Abstract

lncRNAs are related to the progression of various diseases, including oral squamous cell carcinoma (OSCC), which is a common squamous cell carcinoma of the head and neck. Tumor-associated macrophages and tumor cells are significant components of tumor microenvironment. M2 polarization of tumor-associated macrophages is a crucial actor in tumor malignancy and metastasis. In this study, we studied the molecular mechanism of lncRNA DCST1-AS1 in OSCC. Here, we reported that DCST1-AS1 was significantly increased in OSCC cells. We found that loss of DCST1-AS1 obviously inhibited the proliferation, migration, and invasion of OSCC cells and xenograft tumor growth. Meanwhile, silencing of DCST1-AS1 also repressed the percentage of macrophages expressing M2 markers CD206 and CD11b. DCST1-AS1 shRNA enhanced the percentage of macrophages expressing M1 markers CD80 and CD11c. Then, we observed that loss of DCST1-AS1 suppressed OSCC progression via inactivating NF-κB signaling. As well established, NF-κB signaling exerts critical roles in tumor progression, and our study proved that DCST1-AS1 could regulate NF-κB signaling. We proved that blocking the NF-κB pathway using antagonists greatly downregulated OSCC progression and M2 macrophage polarization induced by the overexpression of DCST1-AS1. To sum up, we reported that DCST1-AS1 plays an important role in modulating OSCC tumorigenicity and M2 macrophage polarization through regulating the NF-κB pathway.

Highlights

  • Head and neck cancer is a sixth most frequent malignant tumor worldwide [1]

  • We found that the expression level of DCST1-AS1 in oral squamous cell carcinoma (OSCC) cell lines (SCC-9, FaDu, Cal27, SCC-25, and HN4 cells) was upregulated than that in NHOK cells (Figure 1(a))

  • It is important to understand the molecular mechanisms of OSCC progression

Read more

Summary

Introduction

Head and neck cancer is a sixth most frequent malignant tumor worldwide [1]. OSCC is the most common type of head and neck cancer [2]. Almost 300000 new cases are reported each year, and over 140000 patients die due to OSCC [3]. Surgery, radiation, and chemoradiation are the primary treatment for OSCC. But the overall 5-year survival of OSCC patients still remained low [4]. The molecular mechanisms of OSCC progression and development are in urgent need to identify more treatment

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.